EDCTP and TDR partner on clinical development fellowship
Scientists from low- and middle-income countries will soon be able to apply once for twice the fellowship opportunities. Today, TDR and EDCTP, the European & Developing Countries Clinical Trials Partnership, signed an agreement that will harmonize and streamline their two fellowship programmes. TDR will offer around 7-8 positions per year and EDCTP up to 10 positions per year.
EDCTP Executive Director Charles Mgone highlighted the value of this partnership. He said, “I am very happy we bring our resources together in partnership and offer African researchers easier access to competitive funding opportunities.” TDR Director John Reeder said, “This is a win-win for all involved. Scientists get more opportunities and we’re being more efficient with the funding provided by our donors.”
Each programme offers scientists and clinical staff hands-on experience with pharmaceutical companies and product development organizations in clinical product development processes. Participants learn how to improve standards of study design, project management, clinical and safety monitoring and data reporting.
“This is a win-win for all involved. Scientists get more opportunities and we’re being more efficient with the funding provided by our donors.”
Dr John ReederTDR Director
The TDR Career Development Fellowships (CDF) programme, which was developed with the help of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), offers targeted training anywhere in the world to enhance competencies in clinical trials for drugs, vaccines and diagnostics on a broad range of infectious diseases of poverty.
EDCTP has an arrangement with the European Federation of Pharmaceutical Industries and Associations (EFPIA) to offer similar placements in European-based companies. EDCTP’s focus is on clinical trials of new or improved drugs, vaccines, microbicides and diagnostics for HIV/AIDS, tuberculosis, malaria, and neglected infectious diseases.
The partnership should increase opportunities and efficiencies for scientists in a number of ways. Applications will be collected centrally and considered in a wider pool. The process and forms will be the same, and applicant backgrounds will be shared with more pharmaceutical companies.
A joint call for applications will be published soon. The partnership will conduct the review and selection process together, with the training programmes inter-related. The selection committee will be composed of experts identified by EDCTP and TDR. Administrative processes and budget management will remain separate under the management of each organization.